found that in breast cancer patients receiving anti-PD-1/PD-L1 therapy, the expression of Tyrosine-Protein Kinase Receptor 3 (TYRO3) in cancer tissues is often positively correlated with poor prognosis (122). Here, TYRO3 is linked to breast carcinoma.